<DOC>
	<DOC>NCT01507285</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to assess the safety and tolerability (maximum tolerated dose) after single and multiple doses of NNC 90-1170 (liraglutide) in healthy volunteers and in subjects with type 2 diabetes.</brief_summary>
	<brief_title>Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>HEALTHY VOLUNTEERS Healthy subjects aged 1845 years inclusive Healthy subjects are defined as individuals free from significant cardiac, pulmonary, gastrointestinal, hepatic, renal, haematological, neurological and psychiatric disease as determined by history, physical examination and clinical laboratory test results Women who are not of childbearing potential Signed and dated written informed consent obtained Body mass index (BMI) within the range 1930 kg/m^2, inclusive SUBJECTS WITH DIABETES Subjects aged 4070 years inclusive Subjects diagnosed with type2 diabetes and a duration of diabetes of more than 12 months Women who are not of childbearing potential Signed and dated written informed consent obtained Fasting Cpeptide at least 0.3 nmol/l and blood glucose at least 7 mmol/l Subjects currently on diet and/or OHA (oral hypoglycemic agents) for at least six months Body mass index (BMI) below 35 kg/m^2 HbA1c (glycosylated haemoglobin) below 11% Stable on current medication for at least 3 weeks prior to dosing in this study HEALTHY VOLUNTEERS Clinically relevant abnormal history or physical findings (e.g. cancer) at the screening assessment, which could interfere with the objectives of the study or the safety of the subject's participation Clinically relevant abnormalities of laboratory values or ECG at the screening evaluation Presence of acute or chronic illness sufficient to invalidate the subject's participation in the study or to make it unnecessarily hazardous Blood pressure and heart rate in seated position at the screening examination outside the ranges 90150 mmHg systolic, 4090 mmHg diastolic: heart rate 40100 beats/min History of drug or alcohol abuse (alcohol abuse is defined as intake of more than 28 units weekly in men and more than 21 units weekly in women) Alcohol intake within 48 hours prior to visit Evidence of drug abuse on urine testing at study entry The subject smokes 10 cigarettes or more, or the equivalent, per day and is unable to refrain from smoking during 3 days prior to the first dosing day and during the confinement period Hepatitis B surface antigen (HBsAg), Hepatitis C antibodies or HIV (human immunodeficiency virus) antibodies History of significant drug allergy or drug hypersensitivity SUBJECTS WITH DIABETES Use of any drug (except for oral hypoglycaemic agents (OHAs)) which in the Investigator's opinion could interfere with the blood glucose level (e.g. insulin, systemic corticosteroids, thiazides) Recurrent severe hypoglycaemia as judged by the Investigator Clinically relevant abnormal history or physical findings (e.g. cancer) at the screening assessment, which could interfere with the objectives of the study or the safety of the subject's participation Clinically relevant abnormalities of laboratory values or ECG at the screening evaluation Presence of acute or chronic illness sufficient to invalidate the subject's participation in the study or to make it unnecessarily hazardous Blood pressure and heart rate in seated position at the screening examination outside the ranges 110160 mmHg systolic, 6090 mmHg diastolic: heart rate 40100 beats/min History of drug or alcohol abuse (alcohol abuse is defined as intake of more than 28 units weekly in men and more than 21 units weekly in women) Alcohol intake within 48 hours of visit Evidence of drug abuse on urine testing at study entry The subject smokes 10 cigarettes or more, or the equivalent, per day and is unable to refrain from smoking during 3 days prior to the first dosing day and during the confinement period Hepatitis B surface antigen (HBsAg), Hepatitis C antibodies History of significant drug allergy or drug hypersensitivity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>